Select Page

The Vaxzevria (AstraZeneca) vaccine, like all other vaccines for COVID-19, was tested extensively before entering the market. The Vaxzevria (AstraZeneca) vaccine is not linked to an increased general risk of developing blood clots (thromboembolic events). If detected in time, most blood clot symptoms respond well to treatment.  The Vaxzevria (AstraZeneca) vaccine is effective and definitely suitable to prevent severe or fatal progression of Covid-19. However, if side effects persist or if you experience new side effects (such as dizziness, persistent headaches, blurred vision, shortness of breath, arm or leg pain, etc.) you should seek immediate medical attention for symptoms of thromboembolic events.  National expert committees support the use of the Vaxzevria (AstraZeneca) vaccine as the benefits of the vaccine in combating the threat of Covid-19 outweigh the risk of side effects. The vaccine saves lives every day.